The U.S. acting attorney general signed an order Thursday reclassifying state-licensed medical marijuana from Schedule I to Schedule III under federal law - a shift that stops well short of federal legalization but delivers something licensed operators have wanted for years: relief from Section 280E of the Internal Revenue Code. The order, signed by Todd Blanche under authority granted to the attorney general through international treaty obligations, also sets up a DEA registration pathway for state-licensed medical producers and distributors, and removes barriers to cannabis research that have persisted for decades.
What 280E Relief Actually Means for Operators
To understand why this matters to a dispensary owner, you have to understand what 280E has done to cannabis business economics. Because marijuana remained a Schedule I controlled substance, businesses trafficking in it were prohibited from deducting ordinary business expenses on their federal taxes - rent, payroll, marketing, utilities, POS system costs, compliance software subscriptions. The effective tax rate for many licensed cannabis retailers has run far above what comparable businesses in other industries pay, because they were taxed on gross profit rather than net income.
Schedule III changes that. Businesses operating within state-licensed medical marijuana programs can now deduct standard business expenses, the same as a liquor retailer or a pharmacy. For multi-state operators running both medical and adult-use programs, the accounting picture gets more complicated - and that's worth flagging before anyone restructures their books. Recreational marijuana not distributed through a state medical program remains Schedule I under Thursday's order, meaning the 280E burden stays in place for the adult-use side of a dual-license operation. Operators with blended medical and recreational revenue will need precise SKU-level tracking and careful separation of cost allocations to substantiate which expenses belong to which license category. That's a compliance headache, but a manageable one compared to the baseline tax exposure they've been carrying.
The DEA Registration Question Is Not Yet Settled
Blanche's order establishes an expedited registration process for state-licensed medical marijuana producers and distributors with the DEA. In practice, what that looks like - application timelines, fee structures, documentation requirements - is not yet defined in detail. Operators should treat this as a process that is being built in real time rather than a door that is already open.
Here's the catch: the order carves state-licensed medical programs out of Schedule I, but the broader reclassification process - covering marijuana more broadly - is still underway. The Trump administration said Thursday it was setting a hearing for late June to begin that wider review. That means the regulatory architecture dispensary operators work inside could shift again, and compliance teams should be watching the DEA docket, not just state agency bulletins.
For states where the same licensed retail store serves both registered medical patients and adult-use consumers - a common setup in markets like Washington - the operational line between Schedule I and Schedule III inventory is not yet clear. Whether a retail location's registered patient sales constitute distribution through a "state medical marijuana program" within the meaning of the order is the kind of question that will need regulatory guidance, and probably legal counsel, before operators make major structural decisions.
Research Access Opens, Which Matters More Than It Sounds
Thursday's order makes explicit that cannabis researchers working with state-licensed marijuana or marijuana-derived products will not face federal penalty. That sounds procedural. It isn't. The Schedule I classification has been the primary structural obstacle to clinical research on cannabis - not because scientists lacked interest, but because the regulatory burden of obtaining federally approved research-grade marijuana, separate from the state-licensed supply chain, made meaningful studies expensive and slow.
For the industry, more research data carries real commercial consequences. Operators and brands that have been making cautious, compliant claims about their products - because robust clinical evidence simply wasn't available to support anything stronger - stand to benefit from a pipeline of credible studies. Better evidence strengthens the case for cannabis as a legitimate medical product category, which in turn supports formulary inclusion, insurance conversations, and the longer-term positioning of dispensaries as healthcare-adjacent retail environments. None of that happens quickly. But the research barrier coming down is the mechanism that makes it possible at all.
What Operators Should Watch Next
The American Trade Association for Cannabis and Hemp called this "the most significant federal advancement in cannabis policy in over 50 years" - and on the tax and research dimensions, that's not an unreasonable characterization. But licensed operators should resist treating Thursday's order as the end of a policy fight rather than a significant inflection point in one that's still moving.
A few things worth tracking closely:
- The broader rescheduling hearing scheduled for late June - its outcome will determine whether adult-use marijuana operators eventually see similar 280E relief
- IRS guidance on how expense deductions apply to operations that hold both medical and recreational licenses in the same state
- DEA registration procedures as they are published - operators in states with robust seed-to-sale tracking and compliance infrastructure are likely better positioned to meet federal registration requirements
- State-level tax structures, which are independent of federal scheduling and will not automatically adjust in response to this order
Opponents of the policy shift have argued publicly that loosening federal oversight sends the wrong signal about cannabis risk at a moment when product potency in state-legal markets has increased significantly. That political pressure is real, and it has backing from more than 20 Republican senators who urged the administration to hold the Schedule I line. The policy is moving, but the debate around it isn't over - and operators who assume Thursday's order settles the federal cannabis question permanently are reading the room too optimistically.
What is clear: for medical marijuana licensees operating inside compliant state frameworks, the tax math just changed. That's not nothing. It's arguably the most concrete financial benefit the federal government has extended to licensed cannabis businesses in the program's entire history.
